CharleneMarieFaresMD

Physician

Dr. Fares is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2015 - 2018
Keck School of Medicine of the University of Southern CaliforniaClass of 2015

PubMed

422 citations
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M. Fares, Eliezer M. Van Allen, Charles G. Drake, James P. Allison, Siwen Hu-Lieskovan
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2019-05-17
8 citations
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach, Jaklin Gukasyan, Charlene M. Fares
Lung Cancer. 2021-08-30
21 citations
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
Amy L. Cummings, Jaklin Gukasyan, Henry Lu, Tristan Grogan, Gemalene Sunga
Nature Cancer. 2020-11-16

Journal Articles

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu, Tristan Grogan, Gemalene Sunga, Charlene M. Fares, Nicholas Hornstein, Jesse Zaretsky, James Carroll, Benjamin Bachrach,..., Nature Cancer, 11/16/2020